Tyler J. Varisco

Nov 16, 2024 | ajpe.org | Aayna Shamsi |Tyler J. Varisco |Matthew A. Wanat |Liz Coyle

Keywordsemotional intelligenceleadershipacademic performancepharmacy studentEQ-i 2.0Get full text accessLog in, subscribe or purchase for full access. References1. RivkinA. Accreditation and Guidance-Driven Curricular Quality Improvements to Adequately Prepare Doctor of Pharmacy Graduates for Entry-Level Practice. [Doctoral dissertation]. Teaneck, NJ: Fairleigh Dickinson University; 2022. 2. American Association of Colleges of Pharmacy.

Jun 11, 2024 | healio.com | Michael Monostra |Richard Smith |Susan Cornell |Tyler J. Varisco

Susan Cornell, PharmD, CDE, FAPhA, FAADE The old adage of “drugs don’t work in people that do not take them,” holds true more today than ever before. Today, there are many limitations for people to get the medications that they need to better manage their diabetes and related conditions. It is true that the cost of medications is skyrocketing.

May 30, 2024 | bmjopen.bmj.com | James Thornton |Tyler J. Varisco |Harshil Patel |Mina Shrestha

DiscussionThe requirements and recommendations set forth by the FDA and CDC back in 2016 put a spotlight on the risk involved with coprescribing benzodiazepines and opioids. Since then, there have been studies showing a decline in coprescribing benzodiazepines and opioids.32 33 In our study, benzodiazepines made up the largest proportion of sedatives being prescribed, potentially reflecting the decision to emphasise the risk of coprescribing this medication with opioids.

Apr 22, 2024 | healio.com | Michael Monostra |Richard Smith |Tyler J. Varisco

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Total expenditures for diabetes medications rose from $27.15 billion in 2011 to $89.17 billion in 2020. Expenditures increased for insulin, incretin mimetics, DPP-IV inhibitors and combination drugs.